Skip to main content
    R

    Reviva Pharmaceuticals Holdings Inc. (RVPH)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • PINK

    $0.35
    -0.04 (-9.13%)

    Market Cap: $4.63M

    Last updated: Nov 13, 2026 at 4:00 PM ET

    Reviva Pharmaceuticals Holdings Inc. (RVPH) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Reviva Pharmaceuticals Holdings reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$19.86M, operating cash flow was -$24.59M and free cash flow was -$24.59M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$2.30M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $20.20M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2018 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Research and development$11.71M$22.91M$31.42M$22.87M$4.85M$295.15K$195.74K$946.30K
    Operating income-$20.20M-$30.80M-$39.50M-$28.23M-$10.10M-$2.43M-$376.86K-$1.12M
    Net income-$19.86M-$29.92M-$39.26M-$28.26M-$8.52M-$3.78M-$846.83K-$1.68M
    EBITDA-$20.14M-$30.24MN/AN/A-$8.51M-$1.47M-$376.21K-$1.12M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating income-$2.43M-$2.62M-$3.27M-$3.56M-$4.03M-$6.07M-$6.54M-$6.28M-$8.46M-$8.13M-$7.92M-$9.62M
    Net income-$2.30M-$2.45M-$3.20M-$3.37M-$4.01M-$6.05M-$6.43M-$6.26M-$8.37M-$7.86M-$7.43M-$9.36M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $406.88K by $14.03M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Total assets$15.92M$15.50M$23.70M$18.92M$31.40M$8.76M$2.60K$65.24M
    Current assets$15.10M$14.68M$23.70M$18.92M$31.40M$8.76M$193$65.24M
    Cash and equivalents$14.44M$13.48M$23.37M$18.52M$29.69M$8.76M$193N/A
    Total liabilities$7.28M$14.69M$17.98M$10.53M$2.72M$3.30M$6.81M$6.09M
    Short-term debt$406.88K$458.15K$0N/AN/AN/A$3.77MN/A
    Long-term debtN/AN/AN/AN/AN/AN/A$3.77MN/A
    Shareholder equity$8.65M$812.57K$5.72M$8.39M$28.69M$5.47M-$6.81M$59.16M
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$18.56M$21.14M$23.56M$15.92M$14.33M$11.63M$7.08M$15.50M$7.63M$8.05M$13.50M$23.70M
    Total liabilities$5.48M$5.93M$6.12M$7.28M$9.78M$12.09M$11.54M$14.69M$17.61M$14.09M$14.84M$17.98M
    Cash and equivalents$17.46M$19.89M$22.19M$14.44M$13.18M$10.36M$5.29M$13.48M$5.56M$6.18M$11.97M$23.37M
    Shareholder equity$13.08M$15.21M$17.44M$8.65M$4.55M-$459.15K-$4.46M$812.57K-$9.98M-$6.04M-$1.35M$5.72M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
    Operating cash flow-$24.59M-$33.54M-$28.32M-$18.96M-$10.67M-$4.07M-$218.44K-$1.07M
    Capital expenditures$3$4$3$0$0$0$0$0
    Free cash flow-$24.59M-$33.54M-$28.32M-$18.96M-$10.67M-$4.07M-$218.44K-$1.07M
    Financing cash flow$25.56M$23.65M$33.17M$7.79M$31.60M$12.83M$100.00K$175.00K
    Fiscal years ended Dec 2018 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$2.18M-$2.12M-$3.80M-$5.80M-$5.59M-$5.01M-$8.19M-$9.10M-$4.24M-$8.48M-$11.73M-$8.88M
    Capital expendituresN/AN/A$0$4$4$0$3$0$0$0$5$0
    Free cash flowN/AN/A-$3.80M-$5.80M-$5.59M-$5.01M-$8.19M-$9.10M-$4.24M-$8.48M-$11.73M-$8.88M
    Last 12 quarters

    Frequently Asked Questions About RVPH

    What is Reviva Pharmaceuticals Holdings' annual revenue?

    Reviva Pharmaceuticals Holdings reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Reviva Pharmaceuticals Holdings profitable?

    No. Reviva Pharmaceuticals Holdings reported net income of -$19.86M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does RVPH generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$24.59M minus capital expenditures of $3 produced free cash flow of -$24.59M.

    How much debt does Reviva Pharmaceuticals Holdings have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $406.88K and cash and equivalents of $14.44M.